A Pilot Study Using Intratympanic Methylprednisolone for Treatment of Persistent Posterior Canal Benign Paroxysmal Positional Vertigo
Department of Otorhinolaryngology, Hospital de Cabueñes, Gijón, Spain
Department of Otorhinolaryngology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Department of Otorhinolaryngology, Hospital Costa del Sol, Marbella, Spain
Department of Genomic Medicine, GENYO - for Genomics and Oncological Research- Pfizer/University of Granada, Otology and Neurotology Gropu, Granada, Spain
OBJECTIVE: To assess the effect of intratympanic methylprednisolone (ITMP) in posterior canal benign paroxysmal positional vertigo (BPPV) that fails treatment involving repositioning maneuver in a case series.
MATERIALS and METHODS: Nine patients with persistent posterior canal BPPV after 6 or more repositioning maneuvers were treated by ITMP (two weekly doses of 0.3–0.4 mL at 40 mg/mL) before repeating the repositioning procedures.
RESULTS: Following ITMP treatment, 7 out of 9 patients were relieved of their symptoms and did not exhibit positional nystagmus after 1 or 2 repositioning maneuvers. The number of positional maneuvers performed before and after ITMP treatment in these 7 patients showed a statistically significant (p=0.016) reduction in the amount of repositioning treatments required. None of the 7 respondent patients showed any relapses during the follow-up period (follow-up range: 11–95 months).
CONCLUSION: Administering ITMP before resuming repositioning procedures can be a useful treatment for persistent BPPV of the posterior canal.